|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||17.29 - 17.29|
|52 Week Range||9.34 - 17.43|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.”
The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder.
U.S. stocks were mixed on Wednesday with the S&P 500 and Dow Jones Industrial Average both dipping, while the Nasdaq Composite advanced slightly in a quiet session the day before Thanksgiving. Asian markets ...
Halozyme Therapeutics saw its shares make a handy gain early on Thursday after the firm announced that it licensed its Enhanze drug-delivery technology to Roche for exclusive development of an “undisclosed ...
U.S. drugmaker Halozyme Therapeutics Inc said on Thursday it would license its drug delivery technology to Bristol-Myers Squibb Co and Swiss drugmaker Roche in separate collaborations. Shares of Halozyme rose 12.7 percent to $14.85 in premarket trading after the company also raised its 2017 revenue forecast as a result of the deals. Halozyme will receive $105 million upfront from Bristol-Myers, while Roche will pay $30 million upfront for Halozyme's Enhanze technology that helps quicken the administration of injectable drugs.
Pharma giant aims to develop cancer drug delivery technology. Halozyme shares are up more than 16% in pre-market trading.
On a per-share basis, the San Diego-based company said it had a loss of 23 cents. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Lion Biotechnologies, XBiotech and Halozyme Therapeutics were among the biotech movers in premarket trading on Friday.
The San Diego-based company said it had a loss of 26 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...
Halozyme Therapeutics, Omeros and Aralez Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.
Why small-cap biotech stocks Coherus BioSciences, Halozyme Therapeutics, PTC Therapeutics, Radius Health, and Spark Therapeutics could soar.
On a per-share basis, the San Diego-based company said it had a loss of 21 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Halozyme Therapeutics (HALO) could be an interesting stock for investors ahead of earnings, as it has a positive ESP and a favorable Zacks Rank.
Halozyme Therapeutics has been soaring, but one trader apparently believes that further gains will be limited. Our scanners show that 3,838 February 13 calls were sold for $0.90 to $0.95 at the same second ...
A presentation at the J.P. Morgan Healthcare Conference and update on 2017 guidance sent shares sharply lower. Is the market overreacting?
Halozyme Therapeutics, Inc. (HALO) has been on the move lately as the stock has risen by 15.1% in the past four weeks, and it is currently trading well above its 20-Day SMA.